Endothelial cells facilitate cell-based cardiac repair: Progress and challenge

Current Stem Cell Research and Therapy

Volumn 9, Issue 5, 2014, Pages 415-423

  Yuan, Ping ^a   Ma, Xin ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiac repair; Endothelial cells; Stem cells

Indexed keywords

ENDOTHELIN; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BONE MARROW CELL; CARDIAC REPAIR; CELL SURVIVAL; ENDOTHELIUM CELL; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; MYOBLAST; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; ANGIOGENESIS; ANIMAL; CELL COMMUNICATION; HEART DISEASES; HEART MUSCLE; PATHOLOGY; PHYSIOLOGY; REGENERATION; TRANSPLANTATION;

ANIMALS; CELL COMMUNICATION; CELL SURVIVAL; ENDOTHELIAL CELLS; HEART DISEASES; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATION; STEM CELL TRANSPLANTATION;

EID: 84907372501     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X09666140710100143     Document Type: Article

References (108)

1. MarinGarcia J. Heart Failure Bench to Bedside. New York: Humana press; 2010.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128(16): E240-E327.
3. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 2003; 83(1): 59-115.
4. Woodcock EA, Matkovich SJ. Cardiomyocytes structure, function and associated pathologies. International Journal of Biochemistry & Cell Biology 2005; 37(9): 1746-1751.
5. Hwa C, Sebastian A, Aird WC. Endothelial biomedicine: Its status as an interdisciplinary field, its progress as a basic science, and its translational bench-to-bedside gap. Endothelium-Journal of Endo-thelial Cell Research 2005; 12(3): 139-151.
6. Roura S, Galvez-Monton C, Bayes-Genis A. The challenges for cardiac vascular precursor cell therapy: lessons from a very elusive precursor. J Vasc Res 2013; 50(4): 304-323.
7. Davies PF, Remuzzi A, Gordon EJ, Dewey CF, Jr., Gimbrone MA, Jr. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc Natl Acad Sci USA 1986; 83(7): 2114-2117.
8. Karimova A, Pinsky DJ. The endothelial response to oxygen deprivation: biology and clinical implications. Intensive Care Med 2001; 27(1): 19-31.
9. Murry CE, Reinecke H, Pabon LM. Regeneration gaps-Observations on stem cells and cardiac repair. J Am Coll Cardiol 2006; 47(9): 1777-1785.
10. Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res 1998; 83(1): 15-26.
11. Soonpaa MH, Field LJ. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. American Journal of Physiology-Heart and Circulatory Physiology 1997; 272(1): H220-H226.
12. Owens AT, Jessup M. The Year in Heart Failure. J Am Coll Car-diol 2012; 60(5): 359-368.
13. Roger VL. Epidemiology of heart failure. Circ Res 2013; 113(6): 646-659.
14. Daubert JC, Saxon L, Adamson PB, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace 2012; 14(9): 1236-1286.
15. Toyoda Y, Guy TS, Kashem A. Present Status and Future Perspectives of Heart Transplantation. Circulation Journal 2013; 77(5): 1097-1110.
16. Menasche P, Alfieri O, Janssens S, et al. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial-First randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117(9): 1189-1200.
17. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012; 307(16): 1717-1726.
18. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ. Cell therapy for cardiac repair-lessons from clinical trials. Nat Rev Cardiol 2014; 11(4): 232-246.
19. Medicine UNLo: ClinicalTrials.gov [online].http://clinicaltrialsgov/ct2/show/NCT01569178 2011.
20. Brunt KR, Weisel RD, Li RK. Stem cells and regenerative medicine-future perspectives. Can J Physiol Pharmacol 2012; 90(3): 327-35.
21. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012, 2: CD006536.
22. Durrani S, Konoplyannikov M, Ashraf M, Haider KH. Skeletal myoblasts for cardiac repair. Regen Med 2010, 5(6): 919-932.
23. Ott HC, Kroess R, Bonaros N, et al. Intramyocardial microdepot injection increases the efficacy of skeletal myoblast transplantation. Eur J Cardiothorac Surg 2005; 27(6): 1017-1021.
24. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 1996; 98(11): 2512-23.
25. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol 2000; 149(3): 731-740.
26. Menasche P, Hagege AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003; 41(7): 1078-1083.
27. Ferreira-Cornwell MC, Luo Y, Narula N, Lenox JM, Lieberman M, Radice GL. Remodeling the intercalated disc leads to cardiomyopa-thy in mice misexpressing cadherins in the heart. J Cell Sci 2002; 115(Pt 8): 1623-1634.
28. Hiasa K, Egashira K, Kitamoto S, et al. Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endo-thelial growth factor. Basic Research in Cardiology 2004; 99(3): 165-172.
29. Matsuzaki Y, Kinjo K, Mulligan RC, Okano H. Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. Immunity 2004, 20(1): 87-93.
30. Calloni R, Cordero EA, Henriques JA, Bonatto D. Reviewing and updating the major molecular markers for stem cells. Stem Cells Dev 2013; 22(9): 1455-1476.
31. Kawada H, Fujita J, Kinjo K, et al. Non-hematopoietic bone marrow cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction: Possible contribution of mesenchymal stem cells. Blood 2004; 104(11): 736a.
32. Mangi AA, Noiseux N, Kong DL, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nature Medicine 2003; 9(9): 1195-1201.
33. Timmermans F, Van Hauwermeiren F, De Smedt M, et al. Endo thelial outgrowth cells are not derived from CD133+ cells o CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Bio 2007; 27(7): 1572-1579.
34. Fazel S, Cimini M, Chen L, et al. Cardioprotective c-kit+ cells ar from the bone marrow and regulate the myocardial balance of an giogenic cytokines. J Clin Invest 2006; 116(7): 1865-1877.
35. Duran JM, Makarewich CA, Sharp TE, et al. Bone-derived stem cells repair the heart after myocardial infarction through transdif ferentiation and paracrine signaling mechanisms. Circ Res 2013 113(5): 539-552.
36. Tomita S, Li RK, Weisel RD, et al. Autologous transplantation o bone marrow cells improves damaged heart function. Circulatio 1999; 100(19): 247-256.
37. Tendera M, Wojakowski W, Ruzyllo W, et al. Intracoronary infusion of bone marrow-derived selected CD34(+)CXCR4(+) cell and non-selected mononuclear cells in patients with acute STEM and reduced left ventricular ejection fraction: results of random ized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009; 30(11): 1313-1321.
38. Strauer BE, Yousef M, Schannwell CM. The acute and long-ter effects of intracoronary Stem cell Transplantation in 191 patient with chronic heARt failure: the STAR-heart study. Eur J Heart Fai 2010; 12(7): 721-729.
39. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection o mononuclear bone marrow cells in acute myocardial infarction. Engl J Med 2006; 355(12): 1199-1209.
40. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronar infusion of mononuclear cells from bone marrow or periphera blood compared with standard therapy in patients after acute myo cardial infarction treated by primary percutaneous coronary inter vention: results of the randomized controlled HEBE trial. Eur Hear J 2011; 32(14): 1736-1747.
41. Wen YT, Meng L, Xie J, Ouyang JA. Direct autologous bone mar row-derived stem cell transplantation for ischemic heart disease: meta-analysis. Expert Opinion on Biological Therapy 2011; 11(5) 559-567.
42. Bondue A, Lapouge G, Paulissen C, et al. Mesp1 acts as a maste regulator of multipotent cardiovascular progenitor specification Cell Stem Cell 2008; 3(1): 69-84.
43. Vincent SD, Buckingham ME. How to make a heart: the origin an regulation of cardiac progenitor cells. Curr Top Dev Biol 2010; 90 1-41.
44. Spater D, Abramczuk MK, Buac K, et al. A HCN4+ cardiomyo genic progenitor derived from the first heart field and human pluri potent stem cells. Nat Cell Biol 2013; 15(9): 1098-1106.
45. Brade T, Pane LS, Moretti A, Chien KR, Laugwitz KL. Embryoni heart progenitors and cardiogenesis. Cold Spring Harb Perspec Med 2013, 3(10): a013847.
46. Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells Proceedings of the National Academy of Sciences of the Unite States of America 2007; 104(35): 14068-14073.
47. Smart N, Bollini S, Dube KN, et al. De novo cardiomyocytes fro within the activated adult heart after injury. Nature 2011 474(7353): 640-644.
48. Zangi L, Lui KO, von Gise A, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 2013; 31(10): 898-907.
49. Baharvand H, Azarnia M, Parivar K, Ashtiani SK. The effect o extracellular matrix on embryonic stem cell-derived cardiomyo cytes. Journal of Molecular and Cellular Cardiology 2005; 38(3) 495-503.
50. Park SW, Koh YJ, Jeon J, et al. Efficient differentiation of huma pluripotent stem cells into functional CD34(+) progenitor cells b combined modulation of the MEK/ERK and BMP4 signalin pathways. Blood 2010; 116(25): 5762-5772.
51. James D, Nam HS, Seandel M, et al. Expansion and maintenanc of human embryonic stem cell-derived endothelial cells by TG beta inhibition is Id1 dependent. Nature Biotechnology 2010 28(2): 161-U115.
52. Menard C, Hagege AA, Agbulut O, et al. Transplantation of car diac-committed mouse embryonic stem cells to infarcted shee myocardium: a preclinical study. Lancet 2005, 366(9490): 1005-1012
53. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-676.
54. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-1920.
55. Liao B, Bao X, Liu L, et al. MicroRNA cluster 302-367 enhances somatic cell reprogramming by accelerating a mesenchymal-to-epithelial transition. J Biol Chem 2011; 286(19): 17359-17364
56. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322(5903): 949-953.
57. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient repro-gramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7(5): 618-630.
58. Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013; 341(6146): 651-654.
59. Forte G, Pagliari S, Pagliari F, Ebara M, Di Nardo P, Aoyagi T. Towards the generation of patient-specific patches for cardiac repair. Stem Cell Rev 2013; 9(3): 313-325.
60. van Laake LW, van Donselaar EG, Monshouwer-Kloots J, et al. Extracellular matrix formation after transplantation of human embryonic stem cell-derived cardiomyocytes. Cellular and Molecular Life Sciences 2010; 67(2): 277-290.
61. van Empel VPM, Bertrand ATA, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovascular Research 2005; 67(1): 21-29.
62. Singh SS, Kang PM. Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases. Current Pharmaceutical Design 2011; 17(18): 1783-1793.
63. Schulman IH, Hare JM. Key developments in stem cell therapy in cardiology. Regenerative Medicine 2012; 7(6): 17-24.
64. Luo Z, Diaco M, Murohara T, Ferrara N, Isner JM, Symes JF. Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury. Ann Thorac Surg 1997; 64(4): 993-998.
65. Scortegagna M, Cataisson C, Martin RJ, et al. HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood 2008; 111(7): 3343-3354.
66. Fu M. Inflammation in chronic heart failure: what is familiar, what is unfamiliar? Eur J Heart Fail 2009; 11(2): 111-112.
67. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005, 111(3): 363-368.
68. Stevens KR, Kreutziger KL, Dupras SK, et al. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci USA 2009; 106(39): 16568-73.
69. Kamata S, Miyagawa S, Fukushima S, et al. Improvement of Cardiac Stem Cell-Sheet Therapy for Chronic Ischemic Injury by Adding Endothelial Progenitor Cell Transplantation: Analysis of Layer-Specific Regional Cardiac Function. Cell Transplant 2013. [Epub ahead of print].
70. Lui KO, Zangi L, Silva EA, et al. Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. Cell Res 2013; 23(10): 1172-1186.
71. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345(8): 588-595.
72. Moraes F, Paye J, Mac Gabhann F, et al. Endothelial Cell-Dependent Regulation of Arteriogenesis. Circ Res 2013; 113(9): 1076-1086.
73. Gomez-Gaviro MV, Lovell-Badge R, Fernandez-Aviles F, Lara-Pezzi E. The vascular stem cell niche. J Cardiovasc Transl Res 2012; 5(5): 618-630.
74. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metallo-proteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89(3): 201-210.
75. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473(7347): 298-307.
76. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97(6): 512-523.
77. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327(6122): 524-526.
78. Sessa WC. Nitric Oxide as an autocrine and paracrine regulator of vessel function. In: Endothelial biomedicine. edn. Edited by Aird WC. New York, USA: Cambridge university press; 2007: 988-993.
79. Liu VW, Huang PL. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardio-vasc Res 2008; 77(1): 19-29.
80. Bolli R. Cardioprotective function of inducible nitric oxide syn-thase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. Journal of Molecular and Cellular Cardiology 2001; 33(11): 1897-9118.
81. Trochu JN, Bouhour JB, Kaley G, Hintze TH. Role of endothe-lium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 2000, 87(12): 1108-1117.
82. Smith RS, Agata J, Xia CF, Chao L, Chao J. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sciences 2005; 76(21): 2457-2471.
83. Chen LL, Yin H, Huang J. Inhibition of TGF-beta 1 signaling by eNOS gene transfer improves ventricular remodeling after myocar-dial infarction through angiogenesis and reduction of apoptosis. Cardiovascular Pathology 2007; 16(4): 221-230.
84. Chen LL, Zhu TB, Yin H, et al. Inhibition of MAPK signaling by eNOS gene transfer improves ventricular remodeling after myocar-dial infarction through reduction of inflammation. Molecular Biology Reports 2010; 37(7): 3067-3072.
85. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003; 108(18): 2184-2190.
86. Araki M, Hasegawa K, Iwai-Kanai E, et al. Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes. J Am Coll Cardiol 2000; 36(4): 1411-1418.
87. Kakita T, Hasegawa K, Iwai-Kanai E, et al. Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes. Circ Res 2001; 88(12): 1239-1246.
88. Ogata Y, Takahashi M, Ueno S, et al. Antiapoptotic effect of endo-thelin-1 in rat cardiomyocytes in vitro. Hypertension 2003, 41(5): 1156-1163.
89. Takeuchi Y, Kihara Y, Inagaki K, Yoneda T, Sasayama S. Endo-thelin-1 has a unique oxygen-saving effect by increasing contractile efficiency in the isolated rat heart. Circulation 2001, 103(11): 1557-1563.
90. Gaarenstroom T, Hill CS. TGF-beta signaling to chromatin: How Smads regulate transcription during self-renewal and differentiation. Semin Cell Dev Biol 2014. [Epub ahead of print].
91. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007; 74(2): 184-195.
92. Ertl G, Frantz S. Healing after myocardial infarction. Cardiovasc Res 2005; 66(1): 22-32.
93. Werner F, Jain MK, Feinberg MW, et al. Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3. J Biol Chem 2000; 275(47): 36653-36658.
94. Lefer AM, Tsao P, Aoki N, Palladino MA, Jr. Mediation of cardio-protection by transforming growth factor-beta. Science 1990; 249(4964): 61-64.
95. Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM. Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol 2001; 38(6): 930-939.
96. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8(1): 21-43.
97. Goumans MJ, Lebrin F, Valdimarsdottir G. Controlling the angio-genic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 2003; 13(7): 301-307.
98. Behfar A, Zingman LV, Hodgson DM, et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J 2002; 16(12): 1558-1566.
99. Oh H, Chi X, Bradfute SB, et al. Cardiac muscle plasticity in adult and embryo by heart-derived progenitor cells. Ann N Y Acad Sci 2004; 1015: 182-189.
100. Tulloch NL, Muskheli V, Razumova MV, et al. Growth of Engineered Human Myocardium With Mechanical Loading and Vascular Coculture. Circ Res 2011, 109(1): 47-U195.
101. Narmoneva DA, Vukmirovic R, Davis ME, Kamm RD, Lee RT. Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration. Circulation 2004; 110(8): 962-968.
102. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 2007; 445(7124): 177-182.
103. Duda DG, Cohen KS, Scadden DT, Jain RK: A protocol for pheno-typic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2007; 2(4): 805-810.
104. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of alloge-neic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012; 308(22): 2369-2379.
105. Tongers J, Losordo DW, Landmesser U. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J 2011; 32(10): 1197-1206.
106. Perin EC, Silva GV, Henry TD, et al. A randomized study of tran-sendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011; 161(6): 1078-1087 e1073.
107. George JC, Goldberg J, Joseph M, et al. Transvenous intramyocar-dial cellular delivery increases retention in comparison to intra-coronary delivery in a porcine model of acute myocardial infarction. J Interv Cardiol 2008; 21(5): 424-431.
108. Hatzistergos KE, Blum A, Ince T, Grichnik JM, Hare JM. What Is the Oncologic Risk of Stem Cell Treatment for Heart Disease? Circ Res 2011; 108(11): 1300-1303.